AOD-9604 research

The AOD-9604 evidence base cited here is 6 sources — 2 clinical, 2 preclinical, 2 regulatory. Its strongest evidence is human — 2 clinical studies, most recently 2014 ("Safety and Metabolism of AOD-9604 as Nutraceutical Ingredient"). Regulatory status: Not FDA-approved (GRAS in AU).

The most useful comparison is against what actually works for weight loss today. This is the context that matters for anyone evaluating AOD-9604 as a fat-loss strategy.

In an era where GLP-1 agonists deliver 15–25% body-weight reduction in large rigorous trials, AOD-9604's modest and ultimately negative clinical results are hard to justify as a primary weight-management approach.

• AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal fat-metabolizing fragment of human growth hormone (residues 176–191) with a tyrosine added at the N-terminus — engineered to isolate HGH's lipolytic effect without its growth-promoting, IGF-1-raising, or diabetogenic effects.
• It is meant to work by upregulating the beta-3 adrenergic receptor (β3-AR) to stimulate fat breakdown (lipolysis) while inhibiting new fat formation (lipogenesis); β3-AR-knockout mice are completely unresponsive, confirming that pathway is essential.
• The most important fact about it: the definitive 24-week Phase IIb obesity trial (n=536) FAILED its primary endpoint — no statistically significant weight loss vs placebo — and the developer terminated obesity development in March 2007.

AOD-9604 ("Anti-Obesity Drug 9604") is a synthetic fragment of the C-terminal region of human growth hormone, designed in 1990s Australia to capture HGH's fat-burning activity without its other hormonal effects. Mechanistically it is elegant — isolate the lipolytic domain, drop the growth-promoting and insulin-antagonistic parts — and the preclinical results were promising.

AOD-9604 is a 16-amino-acid peptide corresponding to HGH residues 176–191, with a tyrosine substituted at the N-terminus. In the 1990s, Frank Ng and colleagues at Monash University (Melbourne) found that this C-terminal fragment carried HGH's lipolytic activity, while the growth-promoting and insulin-antagonistic effects came from different structural regions — so synthesizing just this fragment could, in principle, stimulate fat breakdown without the metabolic complications of full-length GH.

Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bridge between the cysteines at positions 7 and 14. Molecular formula C78H123N23O23S2, MW ≈ 1,815 g/mol, CAS 221231-10-3. Metabolic Pharmaceuticals Ltd. licensed it and ran clinical development from 2001 to 2007.

Reported effects are modest relative to approved anti-obesity drugs, and the longer-term data is negative.

• Weeks 1–4: minimal visible change; no significant weight loss expected on available data.
• Weeks 4–8: in the 12-week Phase IIa trial, treated subjects trended toward ~2.6 kg total loss by study end; changes here are incremental and hard to distinguish from normal fluctuation.
• Beyond 12 weeks: the 24-week Phase IIb trial found NO statistically significant difference vs placebo — effects appear to plateau or vanish over longer durations, the key limitation of the evidence.

AOD-9604's development produced a mixed record: strong preclinical results that did not translate into convincing human efficacy.

• With GH secretagogues (CJC-1295 / Ipamorelin) — complementary in theory: AOD-9604 targets lipolysis directly via β3-AR while secretagogues raise endogenous GH for broader metabolic effects (often AOD in the morning fasted, secretagogues before bed).
• With BPC-157 — pairs body-composition aims with tissue repair; BPC-157's anti-inflammatory/healing effects may complement AOD-9604's preliminary cartilage-supportive signal for those with joint issues.
• With other fat-loss agents (tesamorelin, 5-amino-1MQ) — some stack multiple lipolytic agents, though no clinical data supports the combinations and interaction risks are unknown.

AOD-9604 had a favorable safety profile across six clinical trials, with adverse-event rates not significantly different from placebo. Reported effects were mild and transient.

AOD-9604 occupies a complicated regulatory position. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• It separately received GRAS (Generally Recognized As Safe) status as a food ingredient, and a 2014 paper framed it as a 'novel nutraceutical ingredient' — distinct from approval as a therapeutic drug.
• Australia / international: developed in Australia but not approved by the TGA as a therapeutic drug; no regulator worldwide has approved it as a drug. Availability varies, mostly for research use only.

Research-grade AOD-9604 is for laboratory research only and is not intended for human use.

AOD-9604 is prohibited in competitive sport. WADA classifies it under S0 (substances with no current regulatory approval for human therapeutic use), and as a GH fragment it also falls within the scope of S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics); it is banned at all times, in- and out-of-competition. There was brief public confusion in 2013 (an Australian Crime Commission report suggested it wasn't banned), after which WADA issued a formal statement clarifying that AOD-9604 was and remains prohibited. Tested athletes should assume it will trigger an anti-doping violation.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.